Overview

Tirzepatide is a synthetic peptide developed for research into metabolic signalling, glucose regulation, appetite pathways, and energy balance. It is classified as a dual GIP and GLP-1 receptor agonist, meaning it interacts with two important incretin hormone pathways involved in metabolic function. Unlike compounds that target the GLP-1 receptor alone, Tirzepatide has been designed to activate both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual-receptor mechanism has made Tirzepatide an important subject of research into the relationship between incretin signalling, insulin response, appetite regulation, satiety, and body-weight management. The GLP-1 pathway is involved in several metabolic processes, including glucose-dependent insulin secretion, appetite signalling, and the regulation of gastric emptying. The GIP pathway also contributes to glucose-dependent insulin secretion and plays a role in nutrient and energy metabolism. By targeting both pathways simultaneously, Tirzepatide provides researchers with a unique compound for investigating how combined incretin receptor activation may influence metabolic processes. Research involving Tirzepatide has primarily focused on areas including glucose metabolism, insulin sensitivity, appetite and satiety signalling, energy intake, body-weight regulation, and overall metabolic health. Its dual-action mechanism continues to generate significant scientific interest in the study of metabolic pathways and incretin biology.